AAD VMX 2021: Ixekizumab Outperforms Guselkumab in Patient Adherence When Used as Monotherapy in Psoriasis
No difference was observed in ixekizumab compared with guselkumab when used as concomitant therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.